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Osteosarcoma is an aggressive malignant bone tumor that causes bone destruc-
tion. Although tumor-specific replicating oncolytic adenovirus OBP-301 induces
an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruc-
tion. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone
destruction. In this study, we investigated the potential of combination therapy
with OBP-301 and ZOL against osteosarcomas with bone destruction. The antitu-
mor activity of OBP-301 and ZOL in monotherapy or combination therapy was
assessed using three human osteosarcoma cell lines (143B, MNNG/HOS, SaOS-2).
The cytotoxic effect of OBP-301 and/or ZOL was measured by assay of cell apop-
tosis. The effect of OBP-301 and ZOL on osteoclast activation was investigated.
The potential of combination therapy against tumor growth and bone destruc-
tion was analyzed using an orthotopic 143B osteosarcoma xenograft tumor
model. OBP-301 and ZOL decreased the viability of human osteosarcoma cells.
Combination therapy with OBP-301 and ZOL displayed a synergistic antitumor
effect, in which OBP-301 promoted apoptosis through suppression of anti-apop-
totic myeloid cell leukemia 1 (MCL1). Combination therapy significantly inhibited
tumor-mediated osteoclast activation, tumor growth and bone destruction com-
pared to monotherapy. These results suggest that combination therapy of OBP-
301 and ZOL suppresses osteosarcoma progression via suppression of MCL1 and
osteoclast activation.
O steosarcoma is the most common malignant bone tumorthat occurs in teenagers or adolescents. Owing to recent
advances in standard treatments such as pre- and post-opera-
tive systemic chemotherapy and surgical resection, the 5-year
survival rate of osteosarcoma patients has improved to
60–78%.(1) However, over 20% of osteosarcoma patients still
die from tumor recurrence and distant metastasis. Bone
destruction is a major obstacle in the treatment of patients with
invasive osteosarcoma because highly aggressive osteosarcoma
frequently invades within bone tissues, causes bone destruction
though osteoclast activation and contributes to poor prognosis.
Osteoclasts are mainly activated through the receptor activator
of nuclear factor-kappaB ligand (RANKL)-RANK system,
which further maintains the survival of osteoclasts.(2) Recently,
an osteoclast-targeted therapy has been proposed as a novel
treatment option for aggressive osteosarcoma with bone
destruction.(3) Therefore, the development of novel therapeutic
strategies that target not only tumor growth but also bone
destruction is required to improve the clinical outcome in
patients with aggressive osteosarcomas.
As a novel therapeutic strategy for targeting tumor cells,
we generated a telomerase-specific replication-competent
oncolytic adenovirus, OBP-301 (Telomelysin).(4) OBP-301 is
a genetically engineered serotype 5 adenovirus, in which the
human telomerase reverse transcriptase (hTERT) promoter
drives the expression of the E1A and E1B genes linked to an
internal ribosome entry site (IRES).(4,5) The hTERT pro-
moter-driven OBP-301 replicates in telomerase-positive tumor
cells, but not in telomerase-negative normal cells. We con-
firmed the antitumor effect of OBP-301 against epithelial and
mesenchymal types of malignant tumor cells in monother-
apy(4–6) and in combination therapy with radiation or
chemotherapy.(7,8) Based on these preclinical studies, a phase
I clinical study of OBP-301, which was conducted in the
United States on patients with advanced solid tumors, indi-
cated that OBP-301 was well tolerated by patients.(9) How-
ever, in an orthotopic osteosarcoma xenograft tumor model,
OBP-301 could not efficiently inhibit osteosarcoma-induced
bone destruction.(10) Thus, for clinical application of OBP-
301 in osteosarcoma patients with bone destruction, a novel
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therapeutic strategy for the suppression of both tumor growth
and bone destruction is needed to improve the therapeutic
potential of OBP-301.
Zoledronic acid (ZOL) is a third-generation bisphosphonate,
which can inhibit bone destruction in patients with metastatic
bone tumors(11–13) or multiple myeloma.(14) Moreover, ZOL
has been shown to exert an antitumor effect against osteosar-
coma cells.(15–17) When ZOL was combined with chemothera-
peutic agents, combination therapy showed a synergistic
antitumor effect against osteosarcoma and prostate cancer
cells.(18,19) A phase I clinical trial of ZOL in combination with
standard chemotherapy against osteosarcoma patients has been
conducted and ZOL was safe and feasible in combination with
chemotherapy.(20) Based on the inhibitory role of ZOL in
osteosarcoma and bone destruction, we hypothesized that ZOL
might enhance the therapeutic potential of OBP-301 for
aggressive osteosarcoma with bone destruction.
In the present study, we investigated the therapeutic poten-
tial of combination therapy of OBP-301 and ZOL against
osteosarcoma with bone destruction. Combination therapy with
OBP-301 and ZOL was assessed based on its effect on the via-
bility of osteosarcoma cells, apoptosis induction, and osteoclast
activation. Additionally, the in vivo antitumor effect of combi-
nation therapy and its effect on bone destruction status were
assessed using an orthotopic osteosarcoma xenograft tumor
model and a three-dimensional computed tomography (3D-CT)
imaging system.
Materials and Methods
Cell lines. The human osteosarcoma cell line 143B and the
mouse macrophage cell line RAW264.7 were purchased from
the American Type Culture Collection (Manassas, VA, USA).
The human osteosarcoma cell line MNNG/HOS was obtained
from DS Pharma Biomedical (Osaka, Japan). The human
osteosarcoma cell line SaOS-2 was kindly provided by Dr.
Satoru Kyo (Shimane University, Izumo, Japan). The normal
human osteoblast NHOst cells and the human osteoclast OCP
cells were purchased from Lonza (Walkersville, MD, USA).
143B and MNNG/HOS cells were maintained in Eagle’s mini-
mum essential medium containing 0.015 mg/mL 5-bromo-20-
deoxyuridine and 1% nonessential amino acids, respectively.
RAW264.7 and SaOS-2 cells were maintained in Dulbecco’s
modified Eagle’s medium. NHOst and OCP cells were main-
tained in One Normal Human Osteoblast Cell Medium Bul-
letKit and in OCP Osteoclast Precursor Medium BulletKit,
respectively. All media were supplemented with 10% fetal
bovine serum, 100 U/mL penicillin, and 100 mg/mL strepto-
mycin. 143B cells stably transfected with the green fluorescent
protein (GFP) expression vector (143B-GFP) and the firefly
luciferase (Luc) expression vector (143B-Luc) were established
and maintained in medium containing Geneticin (Life Tech-
nologies, Tokyo, Japan).
Reagents. Zoledronic acid and mouse recombinant RANKL
was purchased from Novartis Pharma (Tokyo, Japan) and
Wako (Osaka, Japan), respectively.
Recombinant adenovirus. The telomerase-specific, condition-
ally replicating adenovirus OBP-301 (Telomelysin), was previ-
ously constructed and characterized.(4,5)
Cell viability assay. Human osteosarcoma and NHOst cells
(1 9 103 cells) and OCP cells (1 9 104 cells), seeded on
96-well plates, were treated with ZOL (0–10 lM) and/or
were infected with OBP-301 at a multiplicity of infection
(MOI) of 0, 1, 5, 10, 50, 100, or 200 plaque forming units
(PFU)/cell. Cell viability was determined on days 3 and 5
after treatment using the Cell Proliferation Kit II (Roche
Molecular Biochemicals, Indianapolis, IN, USA) according to
the manufacturer’s protocol. The combined effect of ZOL
and OBP-301 was analyzed by calculating the combination
index using CalcuSyn software (BioSoft, Cambridge, UK).
The computation of the combination index was based on the
methods of Chou.(21)
Flow cytometric analysis. The cells, treated with ZOL (0–10
lM), were labeled with mouse anti-coxsackie and adenovirus
receptor (CAR) monoclonal antibody (mAb; RmcB; Upstate
Biotechnology, Lake Placid, NY, USA) for 30 min at 4°C.
The cells were incubated with fluorescein isothiocyanate
(FITC)-conjugated rabbit anti-mouse IgG second antibody
(Zymed Laboratories, San Francisco, CA, USA) and were ana-
lyzed using flow cytometry (FACS Array; BD Bioscience,
Franklin Lakes, NJ, USA). The mean fluorescence intensity
(MFI) of CAR for each cell line was determined by calculating
the difference between the MFI of antibody-labeled and non-
labeled cells from three independent experiments.
The cells (1 9 105 cells), treated with ZOL and OBP-301
for 72 h, were incubated for 20 min on ice in Cytofix/Cytop-
erm solution (BD Biosciences), were labeled with phycoery-
thrin (PE)-conjugated rabbit anti-active caspase-3 mAb (BD
Biosciences) for 30 min, and were then analyzed using a
FACS array (BD Biosciences).
TUNEL staining. Human osteosarcoma 143B and MNNG/
HOS cells (1.0 9 103 cells) and SaOS-2 cells (5.0 9 103
cells/well), seeded on 8-well glass plates, were treated with
ZOL (10 lM) for 72 h. The cells were fixed in 1%
paraformaldehyde for 10 min. After washing, 40,6-diamidino-
2-phenylindole (DAPI; 1 lg/mL) and 0.1% TritonX-100
solution were added and incubated for 10 min at room temper-
ature. Then, cells were incubated with TdT reaction solution
(1 lg terminal deoxynucleotidyle transferase [TdT] and 5 lg
FITC-conjugated deoxyuridine triphosphate [dUTP] in
1200 lL TdT buffer; Roche Diagnostics GmbH, Mannheim,
Germany). The cells were then stained by Hoechst 33258
(10 mg/m) for 15 min at room temperature. The cells were
then observed under a fluorescence microscope.
Western blot analysis. The cells (3 9 105 cells), seeded in
100-mm dishes, were treated with ZOL (0–10 lM) and/or
were infected with OBP-301 (0–200 MOI) for 72 h. The cells
(1 9 105 cells), seeded in 100-mm dishes, were transfected
with 10 nM MCL1 small interfering RNA (siRNA), or control
siRNA (Applied Biosystems, Foster City, CA, USA) using
HiPerfect transfection reagents (Qiagen, Valencia, CA, USA).
Whole-cell lysates were prepared in a lysis buffer (50 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100) contain-
ing a protease inhibitor cocktail (Complete Mini; Roche
Applied Science, Mannheim, Germany). Proteins were elec-
trophoresed on 8–15% sodium duodecyl sulfate polyacrylamide
gels and were transferred to polyvinylidene difluoride mem-
branes (Amersham, Hybond; GE Health Care, Bucking-
hamshire, UK). Blots were blocked with Blocking-One
(Nacalai Tesque, Kyoto, Japan) at room temperature for
30 min. The primary antibodies used were: rabbit anti-poly
(ADP-ribose) polymerase (PARP) polyclonal antibody (pAb;
Cell Signaling Technology, Danvers, MA, USA), anti-Ad5
E1A mAb (BD Biosciences), rabbit anti-E2F1 mAb, rabbit
anti-MCL1 mAb (Cell Signaling Technology), and mouse anti-
b-actin mAb (Sigma-Aldrich, St. Louis, MO, USA). The
secondary antibodies used were: horseradish peroxidase-conju-
gated antibodies against rabbit IgG (GE Healthcare,
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Buckinghamshire, UK), mouse IgG (GE Healthcare), or goat
IgG (Chemicon International Inc., Temecula, CA, USA).
Immunoreactive bands on the blots were visualized using
enhanced chemiluminescence substrates (ECL Plus; GE
Healthcare).
Co-culture of 143B-GFP cells and osteoclasts. A co-culture sys-
tem with 143B-GFP and RAW264.7 cells in the presence of
RANKL, which induces the differentiation of osteoclasts in
RAW264.7 cells 22, was used. RAW264.7 cells (1 9 104
cells), seeded on a 96-well plate, were treated with RANKL
(50 ng/mL) for 72 h. Subsequently, after co-culture with
143B-GFP cells (1 9 103 cells), the cells were treated with
ZOL (5 lM) and/or OBP-301 (1 9 105 PFU) for 72 h. The
number of 143B-GFP cells was observed under a fluorescence
microscope. Tartrate-Resistant Acid Phosphatase (TRAP) stain-
ing was performed using a TRAP staining kit (Cosmo Bio,
Tokyo, Japan) to confirm the number of TRAP-positive
osteoclasts.
In vivo orthotopic 143B-Luc xenograft tumor model. Animal
experimental protocols were approved by the Ethics Review
Committee for Animal Experimentation of Okayama Univer-
sity School of Medicine (No. OKU-2014464). 143B-Luc cells
(2 9 106 cells/site) were inoculated into the left tibias of
female athymic nude mice aged 6 weeks (CLEA Japan,
Tokyo, Japan). Mice were divided into four groups; mock,
ZOL, OBP-301, and combination treatment. One week after
tumor inoculation, phosphate-buffered saline (PBS) containing
OBP-301 (1 9 108 PFU) in a 20 lL volume was injected
into the tumors. PBS containing ZOL (100 lg/kg body
weight [BW]) in a 50 lL volume was intraperitoneally
injected every week for three cycles. To monitor the tumor
growth, the luciferase substrate luciferin (VivoGlo Luciferin;
Promega, Madison, WI, USA) was intraperitoneally injected
at a dose of 150 mg/kg BW. Images were collected once a
week. Images were taken in the right decubitus position after
luciferin injection with the Xenogen IVIS Lumina Imaging
System (Caliper Life Sciences, Cheshire, UK). Photons emit-
ted from the left knee region were quantified by using Xeno-
gen Living Image Software (Caliper Life Science). Body
weight was also measured at the same time as assessment of
tumor growth.
Three-dimensional computed tomography imaging. Bone
destruction was assessed using 3D-CT imaging (ALOKA
Latheta LCT-200; Hitachi Aloka Medical, Tokyo, Japan).
The mice were set in the prone position in the CT scanner.
A CT scan was performed at a slice of every 48 lm from
the distal thigh to the ankle. The CT data were recon-
structed and analyzed using AZE virtual place 99 software
(AZE, Tokyo, Japan). Image quantification of bone volume
was performed based on a radiodensity of Hounsfield units
(HUs).
Histopathological analysis. Tumors including the knee joint
were fixed in 10% neutralized formalin and embedded in
paraffin blocks. Sections were made longitudinally along the
tibia bone and were stained with hematoxylin/eosin to assess
the tumor region. The formation of osteoclast cells was exam-
ined using a TRAP Staining Kit (Cosmo Bio) according to the
manufacturer’s protocol. Immunostaining with rabbit anti-Ki67
mAb (Abcam, Cambridge, MA, USA) was used to detect pro-
liferating tumor cells within tumor tissues. All sections were
analyzed under a light microscope.
Statistical analysis. Data are expressed as mean  SD. A
one-way ANOVA followed by a Dunnett multiple-group compar-
ison test was used to compare differences between groups in
in vivo experiments. Differences between groups were exam-
ined for statistical significance using Student’s t-test. P values
<0.05 were considered statistically significant.
Results
In vitro cytopathic effect of OBP-301 and ZOL against human
osteosarcoma cells. To investigate the therapeutic potential of
OBP-301 and ZOL against osteosarcoma, we used three human
osteosarcoma cell lines (143B, MNNG/HOS, SaOS-2). Both
OBP-301 and ZOL decreased the viability of all cell lines in a
time and dose dependent manner. OBP-301 decreased the via-
bility of MNNG/HOS and SaOS-2 cells more efficiently than
it decreased that of 143B cells, whereas ZOL decreased the
viability of SaOS-2 cells more efficiently than it decreased that
of 143B and MNNG/HOS cells (Fig. 1a,b). These data indi-
cated that 143B cells were relatively resistant to OBP-301 and
ZOL compared with MNNG/HOS and SaOS-2 cells. We next
examined the combined effect of OBP-301 and ZOL on the
viability of human osteosarcoma cells. All human osteosar-
coma cells were concomitantly treated with OBP-301 and
ZOL at various doses for 5 days. Combination treatment of
OBP-301 and ZOL decreased the viability of all human
osteosarcoma cells more efficiently than single treatment
(Fig. 1c). Calculation of the combination index demonstrated a
synergistic antitumor effect for the combination of OBP-301
and ZOL in all human osteosarcoma cells, although a low con-
centration of ZOL in combination with OBP-301 showed an
antagonistic effect in the OBP-301 and ZOL-resistant 143B
cells (Fig. 1d). These results indicate that combination therapy
of OBP-301 and ZOL is more effective antitumor therapy
compared with monotherapy of OBP-301 or ZOL.
ZOL increases CAR expression and infection efficiency of OBP-
301. To explore the mechanism of the synergistic antitumor
effect of the combination therapy with OBP-301 and ZOL, we
next addressed whether ZOL enhances CAR expression, infec-
tion efficiency or the replication rate of OBP-301 in human
osteosarcoma cells. Flow cytometric analysis demonstrated that
ZOL treatment significantly increased CAR expression in all
human osteosarcoma cells (Fig. 2a,b). Consistent with ZOL-
mediated CAR upregulation, the E1A copy number was signifi-
cantly increased in the ZOL-treated 143B and MNNG/HOS
cells, but not in SaOS-2 cells (Fig. 2c). However, there was no
significant difference in the replication rate of OBP-301
between non-treated and ZOL-treated osteosarcoma cells
(Fig. 2c). These results indicate that the synergistic antitumor
effect of the combination therapy is not due to enhancement of
the OBP-301-mediated antitumor effect by ZOL.
OBP-301 enhances ZOL-induced apoptosis. Recent reports
have shown that ZOL induces apoptosis in osteosarcoma
cells.(15–17) Moreover, we recently showed a chemosensitizing
effect of OBP-301 in human malignant tumor cells.(22) To fur-
ther explore the mechanism underlying the synergistic antitu-
mor effect of the combination therapy, we assessed whether
OBP-301 enhances ZOL-mediated apoptosis induction. The
apoptosis-inducing effect of ZOL against osteosarcoma cells
was examined by analysis of apoptotic cells and expression of
cleaved PARP using TUNEL staining and western blot analy-
sis, respectively. These analyses indicated that ZOL induced
the percentage of apoptotic cells and increased expression of
cleaved PARP in all of the human osteosarcoma cells (Fig. 3a,
b and Fig. S1). Next, to evaluate if OBP-301 promotes ZOL-
induced apoptosis, human osteosarcoma cells were treated with
ZOL and OBP-301 for 5 days. Compared with the expression
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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level of cleaved PARP and active caspase-3 in the non-treated
control or in cells treated with monotherapy, the combination
of ZOL and OBP-301 significantly increased the expression of
cleaved PARP and active caspase-3 in human osteosarcoma
cells (Fig. 3c,d). These results indicate that OBP-301 promotes
ZOL-mediated apoptosis induction.
MCL1 suppression is critical for enhancement of ZOL-induced
apoptosis by OBP-301. We previously reported that OBP-301
activates expression of the transcription factor E2F1 in human
cancer cells.(23) Croxton et al. previously reported that E2F1
inhibits the expression of the anti-apoptotic BCL2 family
member, myeloid cell leukemia 1 (MCL1), whose depletion
resulted in the induction of apoptosis.(24) To evaluate if inhibi-
tion of MCL1 expression was involved in the underlying
mechanism by which OBP-301 mediated the enhancement of
ZOL-induced apoptosis, we investigated the effect of OBP-301
on MCL1 expression. OBP-301 increased the expression of
adenoviral E1A and E2F1, whereas it decreased the expression
of MCL1 in all human osteosarcoma cells (Fig. 4a). Further-
more, in 143B and MNNG/HOS cells, the combination of
OBP-301 and ZOL induced apoptosis (PARP cleavage), which
was associated with upregulation of E1A and E2F1 and
Fig. 1. In vitro antitumor effect of OBP-301 and/or zoledronic acid (ZOL) against human osteosarcoma cell lines. (a) Three human osteosarcoma
cell lines (143B, MNNG/HOS, SaOS-2) were infected with OBP-301 and cell viability was assessed over 3 and 5 days using the XTT assay. Data are
expressed as mean values  SD (n = 3). (b) Cells were treated with ZOL and cell survival was quantified. (c) Cell viability was assessed 5 days after
combined OBP-301 and ZOL treatment. (d) The combination index was calculated using CalcuSyn software. Synergism and antagonism were
defined as interaction indices of <1 and >1, respectively.
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downregulation of MCL1, more efficiently compared to
monotherapy with ZOL or OBP-301 (Fig. 4b). To confirm the
functional role of MCL1 suppression in ZOL-mediated apopto-
sis induction, we further assessed the effect of MCL1 knock-
down by RNA interference on ZOL-induced apoptosis. MCL1
siRNA suppressed MCL1 expression and resulted in the
enhancement of ZOL-induced apoptosis in 143B and MNNG/
HOS cells compared to control siRNA (Fig. 4c). These results
suggest that OBP-301 enhances ZOL-mediated apoptosis
induction via MCL1 suppression.
The combination of OBP-301 and ZOL inhibits tumor cell prolif-
eration and osteoclast activation. A recent report showed that
RANKL induces osteoclast differentiation in RAW264.7
cells.(25) Osteoclasts are activated and maintained by osteosar-
coma cells in the process of osteosarcoma-induced bone
destruction.(3) To investigate whether the combination of OBP-
301 and ZOL suppresses the viability of osteoclasts in a tumor
microenvironment, we co-cultured RANKL-treated RAW264.7
cells with 143B-GFP osteosarcoma cells (Fig. 5a). We then
analyzed the effect of OBP-301 and/or ZOL treatment on the
viability of the 143B-GFP osteosarcoma cells and of the
induced TRAP-positive RAW264.7 osteoclasts. OBP-301 sig-
nificantly reduced the viability of 143B-GFP cells regardless
of whether it was combined with or without ZOL (Fig. 5b,c).
In contrast, the number of TRAP-positive osteoclasts was sig-
nificantly inhibited by the combination of OBP-301 and ZOL
Fig. 2. Zoledronic acid (ZOL)-mediated enhancement of coxsackie and adenovirus receptor (CAR) expression and infection efficiency of OBP-
301. (a) Representative histogram of CAR expression in human osteosarcoma cells treated with ZOL. Cells were treated with ZOL for 72 h. The
mean fluorescence intensity (MFI) of CAR expression was assessed by flow cytometric analysis. (b) Quantitative measurement of MFI in CAR
expression. (c) Quantitative measurement of viral DNA replication. Cells were treated with ZOL (10 lM), and E1A copy number was analyzed
using quantitative real-time PCR. Data are expressed as mean values  SD (n = 3). Statistical significance (* and **) was determined as P < 0.05
and P < 0.01, respectively.
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compared to control or OBP-301 treatment alone (Fig. 5b,c).
Furthermore, to determine the effect of OBP-301 and ZOL
against normal cells in the bone microenvironment, normal
human osteoclasts and osteoblasts were treated with ZOL or
OBP-301 for 5 days. ZOL decreased the viability of osteo-
clasts, but not of osteoblasts, whereas OBP-301 did not affect
the viability of either osteoclasts or osteoblasts (Fig. 5d).
These results suggest that combination therapy with OBP-301
and ZOL suppresses the viability of osteoclasts and osteosar-
coma cells without affecting the viability of osteoblasts.
The combination of OBP-301 and ZOL inhibits tumor growth
and bone destruction. Finally, to assess the effect of OBP-301
and ZOL on xenograft tumor growth and tumor-mediated bone
destruction, we used an orthotopic 143B-Luc xenograft
osteosarcoma tumor model. OBP-301 or PBS was injected into
the tumors and ZOL was intraperitoneally injected every week
for three cycles. The combination of OBP-301 and ZOL signif-
icantly suppressed tumor growth, which was evaluated by luci-
ferase activity, when compared to control group (Fig. 6a).
There was no significant difference in the mean body weight
of mice in each treatment group (Fig. S2). Immunohistochemi-
cal analysis demonstrated that combination therapy with
OBP-301 and ZOL significantly decreased the percentage of
Ki67-positive proliferating cells within tumor tissues compared
Fig. 3. OBP-301-mediated enhancement of zoledronic acid (ZOL)-induced apoptosis. (a) Cells were treated with ZOL (10 lM) for 72 h. Apoptotic
cells were visualized by TUNEL staining and were analyzed under a fluorescence microscope. White scale bar, 100 lm. (b) Lysates of cells treated
with the indicated concentrations of ZOL for 72 h were analyzed by Western blotting for PARP and cleaved PARP (C-PARP). b-actin was assayed
as a loading control. (c) Cells were treated with ZOL and/or OBP-301 for 72 h. (d) The percentage of cells with active caspase-3 was quantified
using flow cytometric analysis. Data are expressed as mean values  SD (n = 3). Statistical significance (* and **) was determined as P < 0.05 and
P < 0.01, respectively.
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to control (Fig. 6b). In contrast, 3D-CT indicated that the com-
bination of OBP-301 and ZOL significantly prevented the
reduction in bone volume that was seen in control and OBP-
301 treatment alone (Fig. 6c). Moreover, TRAP staining
demonstrated that the number of osteoclasts in the tibial meta-
physis was significantly suppressed by ZOL or by the combi-
nation of OBP-301 and ZOL (Fig. 6d). These results suggest
that combination therapy with OBP-301 and ZOL efficiently
inhibits osteosarcoma progression and bone destruction through
suppression of osteoclast activation.
Discussion
Osteosarcomas show an aggressive phenotype with bone
destruction. Since the dissemination of osteosarcoma cells into
bone tissues contributes to bone destruction, tumor recurrence,
and poor prognosis, the prevention of bone destruction is a
main obstacle to improving the clinical outcome of osteosar-
coma patients. In this study, we demonstrated that combination
therapy with OBP-301 and ZOL showed a synergistic antitu-
mor effect, which was mainly due to enhancement of apopto-
sis. OBP-301 promoted ZOL-induced apoptosis through
suppression of anti-apoptotic MCL1 expression in osteosar-
coma cells, whereas ZOL suppressed the viability of osteo-
clasts. Furthermore, combination therapy with OBP-301 and
ZOL significantly suppressed both tumor growth and bone
destruction compared to the control group. Thus, combination
therapy of tumor-targeted OBP-301 and bone-targeted ZOL is
a promising antitumor strategy for improvement of the therapy
of bone-invasive osteosarcoma.
Combination therapy with OBP-301 and ZOL showed a syn-
ergistic antitumor effect, in which apoptosis induction was sig-
nificantly and synergistically enhanced. We and our
collaborators recently demonstrated that the antitumor effect of
OBP-301 in human osteosarcoma cells was mediated through
induction of apoptosis- and autophagy-related cell death.(6,10,26)
ZOL has a therapeutic potential to induce apoptosis in human
osteosarcoma cells, as previously shown in other reports.(15–17)
Regarding the underlying mechanism by which OBP-301
enhances ZOL-induced apoptosis, OBP-301 caused the sup-
pression of anti-apoptotic MCL1 expression, which resulted in
enhancement of apoptosis. Although oncolytic adenoviruses
have been previously shown to suppress MCL1 expres-
sion,(27,28) the precise underlying mechanism of virus-mediated
MCL1 suppression remains unclear. Adenoviral E1A accumu-
lation is associated with a reduction in MCL1 expression in
adenovirus-infected cells.(29) Since E1A induces E2F1 activa-
tion(30) and E2F1 overexpression suppresses MCL1 expres-
sion,(24,31) E1A-mediated E2F1 activation would be a critical
factor for OBP-301-mediated MCL1 downregulation. More-
over, E2F1 overexpression has been shown to sensitize human
osteosarcoma U2OS cells to chemotherapeutic agents.(32) We
recently showed that, in combination therapy with OBP-301
and chemotherapeutic agents, OBP-301 suppressed MCL1
expression via E2F1-dependent upregulation of MCL1-target-
ing microRNA-29, and subsequently enhanced chemotherapy-
induced apoptosis in human osteosarcoma cells.(33) A clinical
study of combination therapy of ZOL with chemotherapeutic
agents has recently been evaluated in aggressive osteosarcoma
patients.(20) Therefore, a multimodal antitumor therapy with
OBP-301, ZOL, and chemotherapy may be a promising antitu-
mor strategy for strong induction of the apoptosis of aggressive
osteosarcomas through MCL1 suppression.
Osteosarcoma-mediated bone destruction is mainly caused
by osteoclast activation.(3) Aggressive osteosarcoma cells pro-
mote osteoclast activation and bone resorption activity through
Fig. 4. MCL1 suppression is involved in the OBP-301-enhancemet of zoledronic acid (ZOL)-induced apoptosis. (a) Cells were infected with OBP-
301 for 72 h. Cell lysates were then analyzed by Western blotting for E1A, E2F1, and MCL1. (b) Cells were treated with OBP-301 and/or ZOL for
72 h. Cell lysates were then analyzed by Western blotting for PARP, cleaved PARP (C-PARP), E1A, E2F1, and MCL1. (c) Cells were transfected with
10 nmol/L MCL1 siRNA or control siRNA and were treated with ZOL (5 lM). Cell lysates were then analyzed by Western blotting for PARP, and
MCL1. b-actin was assayed as a loading control.
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the production of RANKL and cytokines.(3,34,35) Since RANKL
has a crucial role in the induction, activation, and survival of
osteoclasts,(3) pharmacological RANKL blockade is expected
to be a promising therapeutic strategy against aggressive
osteosarcoma tumors.(36) ZOL has been shown to inhibit
RANKL production in osteosarcoma cells.(34) However,
osteosarcoma cells further produce some osteotropic factors,
including parathyroid hormone and prostaglandin, which
induce the osteoblast-mediated production of RANKL and sub-
sequent osteoclast activation.(3) Although OBP-301 and ZOL
did not affect the viability of osteoblasts, OBP-301 indirectly
inhibits the activation of osteoclast and osteoblast by inducing
tumor-specific cell death and ablating the RANKL and cyto-
kine network. In contrast, ZOL directly inhibits the survival of
osteoclasts probably through the induction of apoptosis.(37,38)
Thus, the combination treatment of OBP-301 and ZOL may be
a novel promising strategy to suppress tumor-dependent osteo-
clast activation and bone destruction of osteosarcomas with a
bone-invasive phenotype.
Zoledronic acid significantly increased the expression level
of CAR in human osteosarcoma cells. Consistent with this
effect of ZOL, we previously found that histone deacetylase
inhibitor,(39) radiation,(7) and valproic acid(40) also increase the
expression level of CAR in human cancer cells. Although the
infection efficiency of OBP-301 was significantly increased in
143B and MNNG/HOS cells at 2 h after infection, ZOL could
not enhance the replication of OBP-301 during 72 h after
infection. Regarding the replication of hTERT-driven
OBP-301, we recently showed that adenoviral E1A accumula-
tion increases the expression of hTERT mRNA via hTERT
promoter activation, which leads to the enhancement of
hTERT-driven OBP-301 replication in human bone and soft
tissue sarcoma cells.(6) Thus, although ZOL enhances CAR
expression and the infection efficiency of OBP-301 in human
osteosarcoma cells, the replication of hTERT-driven OBP-301
may be mainly enhanced by adenoviral E1A accumulation
rather than by ZOL.
It is worth noting that adenoviral E1A accumulation is sup-
pressed after treatment with OBP-301 and ZOL. E1A protein
Fig. 5. The effect of zoledronic acid (ZOL) and OBP-301 against osteosarcoma cells and osteoclasts in a bone tumor microenvironment. (a)
Scheme of the co-culture of 143B-GFP cells and osteoclast-differentiated RAW264.7 cells. RAW264.7 cells were differentiated to osteoclasts by
adding RANKL (50 ng/mL). (b) Representative photographs of GFP-positive and TRAP-positive (osteoclasts) cells in the co-culture system after
treatment with control, ZOL (5 lM), OBP-301 (1 9 105 PFU), or both ZOL and OBP-301. White scale bar, 200 lm. Black scale bar, 500 lm. (c) The
number of GFP-positive osteosarcoma cells and TRAP-positive osteoclasts following treatment. (d) The viability of normal human osteoblasts and
osteoclasts 5 days after treatment with ZOL or OBP-301. Data are expressed as mean values  SD (n = 3). Statistical significance (*) was deter-
mined as P < 0.05. N.S., not significant.
Cancer Sci | September 2017 | vol. 108 | no. 9 | 1877 © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Yamakawa et al.
expression was decreased by treatment with high concentration
of OBP-301 compared to low concentration of OBP-301
(Fig. 4a). Adenoviral late genes have been suggested to sup-
press the E1A expression during the late phase of adenovirus
infection.(41) In contrast, ZOL treatment suppressed the E1A
protein expression in combination therapy (Fig. 4b). Recent
report has also shown slightly decreased expression of E1A
protein in human mesothelioma cells after treatment with repli-
cation-competent adenovirus Ad-delE1B55 and ZOL.(42) How-
ever, the molecular mechanism underlying the ZOL-mediated
E1A suppression remains unclear. Further experiment would
be warranted to investigate the role of ZOL in the accumula-
tion of adenoviral E1A protein during adenovirus infection.
Bone destruction is caused not only by primary bone tumors
but also by metastatic bone tumors. Bone metastasis is one of
the most common complications in patients with advanced
breast and prostate cancers. ZOL is a clinically available bone-
sparing agent that is used to treat patients with bone metas-
tases.(43) Although ZOL inhibits tumor-mediated osteoclast
activation, the formation of bone metastases was not prevented
by ZOL in a prostate cancer bone metastasis model.(44)
Regarding the underlying mechanism of bone metastasis, meta-
static tumor cells can display a dormancy that causes them to
be refractory to conventional anticancer therapy and to form
metastatic foci.(45) We recently demonstrated that OBP-301
efficiently eliminates dormant cancer stem-like cells with
sphere-forming capacity and resistance to chemoradiotherapy
through modulation of the cell cycle.(46) If OBP-301 has thera-
peutic potential against bone metastasis-initiating dormant can-
cer cells, then combination therapy of OBP-301 and ZOL may
be further beneficial for the improvement of clinical outcome
in advanced cancer patients with metastatic bone tumors.
In conclusion, we demonstrated that combination therapy
with OBP-301 and ZOL exerted a synergistic antitumor effect
Fig. 6. Combination therapy with zoledronic acid (ZOL) and OBP-301 inhibits tumor growth and bone destruction in an orthotopic 143B-Luc
osteosarcoma xenograft model. (a) Seven days after intratibial inoculation of 143B-Luc cells (2.0 9 106 cells/site), ZOL (100 lg/kg) was intraperi-
toneally injected and OBP-301 (1 9 108 PFUs) was injected into the tumor on days 0, 7, and 14. Six mice were used for each group. Representa-
tive images of mice treated with control, ZOL, OBP-301, or both ZOL and OBP-301, on days 0, 14, and 28. (b) The percentage of Ki67-positive
cells in tumor tissue. (c) Representative 3D-CT pictures of the left tibia bone at 28 days after treatment with control, ZOL, OBP-301, or both ZOL
and OBP-301. Bone volume was assessed as total Hounsfield units (HU) from the proximal tibia to 5 mm distal to the sagittal slice. (d) The num-
ber of TRAP-positive osteoclasts in tumor tissue following treatment. Data are expressed as mean values  SD (n = 6 for each group). Statistical
significance (* and **) was determined as P < 0.05 and P < 0.01, respectively. N.S., not significant.
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by promoting apoptotic cell death via OBP-301-mediated
MCL1 suppression. Furthermore, ZOL prevented bone destruc-
tion through inhibition of osteoclast activation. These data sug-
gest that this combination therapy would have great
therapeutic potential as a novel dual targeted strategy against
highly aggressive osteosarcoma with bone destruction. The
administration route of OBP-301 is limited to the local intratu-
moral injection; however, the recent approval of oncolytic her-
pesvirus, talimogene laherparepvec (T-VEC), for melanoma
patients supports the clinical relevance of local administra-
tion.(47) Further clinical studies are warranted to investigate the
tolerability and efficacy of this dual-targeted combination ther-
apy in aggressive osteosarcoma patients.
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